Moreover, two therapeutic approaches, including either oral Tempol treatment or genetic reduction of ferritin expression, delayed neurodegeneration, suggesting possible approaches to treatment if a human neurodegenerative disease attributable to loss of IRP2 is identified in the future. This evidence concerns the gene IREB2 and neurodegenerative disease.